CSL112, A Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Patients With Stable Atherothrombotic Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study
Publication
, Journal Article
Gille, A; D'Andrea, D; Easton, R; Tricoci, P; Alexander, JH; Wright, SD; Shear, CL
Published in: CIRCULATION
November 26, 2013
Duke Scholars
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
November 26, 2013
Volume
128
Issue
22
Location
Dallas, TX
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gille, A., D’Andrea, D., Easton, R., Tricoci, P., Alexander, J. H., Wright, S. D., & Shear, C. L. (2013). CSL112, A Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Patients With Stable Atherothrombotic Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study. CIRCULATION, 128(22).
Gille, Andreas, Denise D’Andrea, Rachel Easton, Pierluigi Tricoci, John H. Alexander, Samuel D. Wright, and Charles L. Shear. “CSL112, A Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Patients With Stable Atherothrombotic Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study.” CIRCULATION 128, no. 22 (November 26, 2013).
Gille A, D’Andrea D, Easton R, Tricoci P, Alexander JH, Wright SD, et al. CSL112, A Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Patients With Stable Atherothrombotic Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study. CIRCULATION. 2013 Nov 26;128(22).
Gille, Andreas, et al. “CSL112, A Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Patients With Stable Atherothrombotic Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study.” CIRCULATION, vol. 128, no. 22, LIPPINCOTT WILLIAMS & WILKINS, Nov. 2013.
Gille A, D’Andrea D, Easton R, Tricoci P, Alexander JH, Wright SD, Shear CL. CSL112, A Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Patients With Stable Atherothrombotic Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2013 Nov 26;128(22).
Published In
CIRCULATION
EISSN
1524-4539
ISSN
0009-7322
Publication Date
November 26, 2013
Volume
128
Issue
22
Location
Dallas, TX
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology